Kenya Launches Cervical Cancer Vaccine

0
4


[Nation] The long-awaited launch of the human papillomavirus (HPV) vaccination is expected to take place in Mombasa Friday.

Related Links:

Conclusion
Results show the importance of OB/GYN visits in obtaining Pap tests for AAPI and NLW students.
Implication for Practice
Health practitioners should pay attention to students’ race/ethnicity in their practice and provide corresponding ethnic group–specific preventive care.

Source: Cancer NursingCategory: Nursing Tags: ARTICLES Source Type: research

[Capital FM] Mombasa -Kenya has rolled out a key vaccine Human Papillomavirus (HPV) to help protect young women against cervical cancer.

[Nairobi News] The Ministry of Health will on Friday roll out the Human Papillomavirus (HPV) virus vaccine against cervical cancer in Mombasa county.

ConclusionsThis is the first large ‐scale randomized clinical trial of HPV vaccination in China. High and sustained vaccine efficacy against HPV‐16/18‐associated infection and cervical lesions was demonstrated up to Month 72. The vaccine had an acceptable safety profile. Combined with screening, prophylactic HPV vaccination cou ld potentially reduce the high burden of HPV infection and cervical cancer in China.Trial registrationNCT00779766.

Source: Cancer MedicineCategory: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research

Abstract
With more than 3300 new cases and almost 2500 deaths each year, cervical cancer (CC) ranks second among female cancers in Moroccan women. The majority of cases occurs in women aged 50 and over. In absence of a national cancer registry, data published in Morocco are limited to the number of cases recorded in some oncology centers, so the incidence of this cancer is likely much higher than estimated. A Moroccan national program against CC based on the practice of visual inspection after application of acetic acid was set up in 2010, allowing both screening and possibly immediate treatment of (pre)cancerous …

Source: Bulletin du CancerCategory: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research

This study aimed to describe and compare vaccine intention among young females with and without a cancer history, in addition to identifying factors associated with a HPV vaccination intention. Vaccine-na ïve females (aged 18–26 years,n = 120) and maternal caregivers with vaccine-naïve daughters (aged 9–17 years,n = 197) completed surveys querying HPV vaccination intention, HPV knowledge, and communication, along with sociodemographic, medical, and health belief factors. Multivariable logistic regression was utilized to calculate odds ratio (OR) and 95% confidence…

Authors: Park YC, Ouh YT, Sung MH, Park HG, Kim TJ, Cho CH, Park JS, Lee JK
Abstract
OBJECTIVE: Persistent infection of HPV increases the chance of carcinoma in situ of cervix through stages of cervical intraepithelial neoplasia (CIN) 1, 2, and 3, and finally progresses into cervical cancer. We aimed to explore the safety and efficacy of BLS-M07 which is orally administered agent expressing human papillomavirus (HPV) 16 E7 antigen on the surface of Lactobacillus casei in patients with CIN 3.
METHODS: Patients with CIN 3 were recruited in our clinical trial. Reid Colposcopic Index (RCI) grading and serum HPV16 E…

OBJECTIVE: To evaluate the knowledge and acceptability of the human papillomavirus (HPV) vaccine among health professionals from western Amazonia. METHODS: A cross-sectional study was conducted in the Sistema Assistencial è Saúde da Mulher e da Criança (Health Care System for Women and Children; SASMC) in Acre, Brazil, in 2017. The participants comprised 196 health professionals. The data collection instrument contained 31 questions about HPV, its clinical repercussions for women, and the HPV vaccine. Quantitative variables were presented as medians and 95% confidence intervals (CIs), and p

Source: ClinicsCategory: General Medicine Source Type: research

Conclusions
The prevalence of the LR-HPV in high-grade squamous intraepithelial lesion cervical lesions is low but is expected to increase in the future because of the expected decrease in CC caused by HPV types that are included in the bi-, quadri-, and nanovalent vaccine. The CIN 2–3 and CC patients with LR-HPV types and with negative HPV, challenge HPV screening sensitivity, which is based on a limited number of HR-HPV types.

Conclusion: Sub-Saharan countries still have a long way to go in controlling the high burden of cervical cancer. Effective prevention methods exist, such as HPV vaccination and screening, but their affordability and implementation remain challenging for most of these countries. Despite that, there is still light on the horizon, as the cost of HPV vaccines has been steadily decreasing and most African countries are using the more cost-effective methods of cervical cancer screening.
PMID: 31552125 [PubMed]

Source: EcancermedicalscienceCategory: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research



Source link